Ablynx secures €1.5 million in grants
The IWT grant allows Ablynx to accelerate its pre-clinical development programme, ALX-0171, for the treatment of respiratory syncytial virus (RSV) infections. ALX-0171 binds to RSV and neutralises the virus. The Nanobody will be administered via the lungs and based on in vivo data, it has the potential to be effective both in the prevention of infection as well as in treatment once infection has occurred.
ALX-0171 is Ablynx's first Nanobody pre-clinical development candidate to be delivered through a route other than injection. Like many Nanobodies, ALX-0171 is very stable, making it suitable for inhalation. It can also be manufactured at relatively low cost in microbial systems.
The grant from the Portuguese government will allow Ablynx and its collaborators, to explore routes of delivery for Nanobodies into the central nervous system (CNS) and to develop Nanobodies against therapeutically relevant CNS targets.
Edwin Moses, CEO and Chairman of Ablynx, said: "We are delighted with IWT's continued support of Ablynx's Nanobody platform as well as with this second grant from the Portuguese government which will allow us to further explore and develop Nanobody-based therapies for CNS diseases where the unmet medical need is very high. Today, we have over 25 therapeutic programmes in our pipeline with four Nanobody products in clinical development."
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.